FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lawrence Flaherty

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Keith T Flaherty; Lawrence E Flaherty; Richard Kefford; Sandra J Lee; Philip Leming; Lynn M Schuchter; Fengmin Zhao; Michael B Atkins; John M Kirkwood
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Kim A Margolin; James Moon; Megan Othus; Wallace L Akerley; Lawrence E Flaherty; John M Kirkwood; Christopher D Lao; Jeffrey A Sosman; Vernon K Sondak
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Elaina Gartner; Percy Ivy; Judith Abrams; Lawrence E Flaherty; Paula Silverman; Michael Steven Simon; Patricia M LoRusso
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lawrence Flaherty (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Keith T Flaherty; Lawrence E Flaherty; Richard Kefford; Sandra J Lee; Philip Leming; Lynn M Schuchter; Fengmin Zhao; Michael B Atkins; John M Kirkwood
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):373-9.
2012: Kim A Margolin; James Moon; Megan Othus; Wallace L Akerley; Lawrence E Flaherty; John M Kirkwood; Christopher D Lao; Jeffrey A Sosman; Vernon K Sondak
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1129-37.
2012: Elaina Gartner; Percy Ivy; Judith Abrams; Lawrence E Flaherty; Paula Silverman; Michael Steven Simon; Patricia M LoRusso
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
Breast cancer research and treatment 2012;131(3):933-7.
2011: Robert B Livingston; Melanie E Royce; Joseph J Kash; Danika L Lew; Kathy S Albain; William E Barlow; Lawrence E Flaherty; Julie R Gralow; Gabriel N Hortobagyi
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Breast cancer research and treatment 2011;130(1):123-31.
2011: Jeffrey A Sosman; Ralph J Tuthill; Joseph M Unger; John T Vetto; James A Warneke; Lawrence E Flaherty; P Y Liu; James Moon; Bruce G Redman; Vernon K Sondak
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
Cancer 2011;117(20):4740-06.
2011: Vernon K Sondak; Lawrence E Flaherty
Targeted therapies: Improved outcomes for patients with metastatic melanoma.
Nature reviews. Clinical oncology 2011;8(9):513-5.
2010: Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).
American journal of clinical oncology 2010;33(5):495-9.
2010: Gary A Croghan; Vera J Suman; William J Maples; Mark Albertini; Gerald Linette; Lawrence E Flaherty; John Eckardt; Cynthia Ma; Svetomir N Markovic; Charles Erlichman
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Cancer 2010;116(14):3463-8.
2010: Joseph I Clark; James Moon; Laura F Hutchins; Jeffrey A Sosman; W Martin Kast; Diane M Da Silva; Ping-Yu Liu; John A Thompson; Lawrence E Flaherty; Vernon K Sondak
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Cancer 2010;116(2):424-31.
2008: Michael B Atkins; Jessie Hsu; Sandra Lee; GARY COHEN; Lawrence E Flaherty; Jeffrey A Sosman; vernon sondak; John M Kirkwood
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5748-54.
2008: vernon sondak; Lawrence E Flaherty
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Lancet 2008;372(9633):89-90.
2008: Jeffrey A Sosman; Carole Carrillo; Walter J Urba; Lawrence E Flaherty; Michael B Atkins; JI Clark; Janet Dutcher; Kim A Margolin; James Mier; Jarod Gollob; John M Kirkwood; David J Panka; Nancy A Crosby; Kevin O'Boyle; Bonnie J Lafleur; Marc S Ernstoff
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2292-8.
2007: Laura F Hutchins; James Moon; Joseph I Clark; John A Thompson; Marianne K Lange; Lawrence E Flaherty; vernon sondak
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Cancer 2007;110(10):2269-75.
2007: Ulka Nitin Vaishampayan; Lance K Heilbrun; Cynthia Marsack; Daryn W Smith; Lawrence E Flaherty
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
Anti-cancer drugs 2007;18(10):1221-6.
2007: Ulka Nitin Vaishampayan; Lance K Heilbrun; Anthony F Shields; Jawana M Lawhorn-Crews; Karen Baranowski; Daryn Smith; Lawrence E Flaherty
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Investigational new drugs 2007;25(1):69-75.
2006: Lata Chandi Thatai; Priya Vishnubhotla; Laura Biernat; Lawrence E Flaherty; Patricia M LoRusso; Michael Steven Simon; Deanna Stephens; Kelly Vereeke; Judith Abrams; David Lee Bouwman; Philip A Philip
A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
American journal of clinical oncology 2006;29(5):484-9.
2005: Ehab Atallah; Lawrence E Flaherty
Treatment of metastatic malignant melanoma.
Current treatment options in oncology 2005;6(3):185-93.
2005: Hyman Muss; Jamie H Von Roenn; Lloyd Earl Damon; Lisa De Angelis; Lawrence E Flaherty; Paul M Harari; Karen Kelly; Michael P Kosty; Matthew J Loscalzo; Robert Mennel; Beverly S Mitchell; Joanne E Mortimer; Franco Muggia; Edith A Perez; Peter W T Pisters; Leonard B Saltz; Lidia Schapira; Joseph A Sparano
ACCO: ASCO core curriculum outline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):2049-77.
2005: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffrey R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):133-41.
2004: Michael Steven Simon; Wei Du; Lawrence E Flaherty; Philip A Philip; Patricia M LoRusso; Cheryl Miree; Daryn Smith; Diane R Brown
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2046-52.
2003: Maha Hussain; Ulka Nitin Vaishampayan; Lance K Heilbrun; Vikash Jain; Patricia M LoRusso; Percy Ivy; Lawrence E Flaherty
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.
Investigational new drugs 2003;21(4):465-71.
2003: Joseph I Clark; Michael B Atkins; Walter J Urba; Steve Creech; Robert A Figlin; Janice P Dutcher; Lawrence E Flaherty; Jeffrey A Sosman; Theodore F Logan; Richard White; Geoffrey R Weiss; Bruce G Redman; Christopher P G Tretter; David F McDermott; John W Smith; Michael S Gordon; Kim Margolin
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3133-40.
2002: Lawrence E Flaherty; Shirish M Gadgeel
Biochemotherapy of melanoma.
Seminars in oncology 2002;29(5):446-55.
2002: Ralph J Tuthill; Joseph M Unger; P Y Liu; Lawrence E Flaherty; vernon sondak
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.
American journal of clinical pathology 2002;118(4):504-11.
2002: John M Kirkwood; Joseph G Ibrahim; vernon sondak; Marc S Ernstoff; Lawrence E Flaherty; Frank J Haluska
Use and abuse of statistics in evidence-based medicine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4122-3; author reply 4123-4.
2002: Jeffrey A Sosman; Joseph M Unger; Ping-Yu Liu; Lawrence E Flaherty; Min S Park; Raymond A Kempf; John A Thompson; Paul I Terasaki; vernon sondak
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2067-75.
2002: vernon sondak; PY Liu; Ralph J Tuthill; Raymond A Kempf; Joseph M Unger; Jeffrey A Sosman; John A Thompson; Geoffrey R Weiss; Bruce G Redman; James G Jakowatz; R Dirk Noyes; Lawrence E Flaherty
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2058-66.
2002: Uma N M Rao; Joseph G Ibrahim; Lawrence E Flaherty; J Richards; John M Kirkwood
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2053-7.
2002: Kim Margolin; B Atkins; A Thompson; S Ernstoff; J Weber; Lawrence E Flaherty; I Clark; G Weiss; Jeffrey A Sosman; W II Smith; P Dutcher; Jared A Gollob; Jeff Longmate; D Johnson
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Journal of cancer research and clinical oncology 2002;128(4):214-8.
2002: Patricia M LoRusso; Sucharu Prakash; Antoinette J Wozniak; Lawrence E Flaherty; Mark M Zalupski; Anthony F Shields; Howard Sands; Ralph E Parchment; Bhaskara R Jasti
Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
Investigational new drugs 2002;20(1):63-71.
2002: Robert P Whitehead; Joseph M Unger; Lawrence E Flaherty; Eric H Kraut; Glenn M Mills; Catherine E Klein; Robert A Chapman; Gary C Doolittle; Neel Hammond; vernon sondak
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
Investigational new drugs 2002;20(1):105-11.
2001: Ulka Nitin Vaishampayan; Lawrence E Flaherty; Wei Du; Maha Hussain
Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Cancer 2001;92(3):519-23.
2001: Lawrence E Flaherty; Michael Atkins; Jeffrey A Sosman; G Weiss; JI Clark; Kim Margolin; Janice Dutcher; Michael S Gordon; Michael Lotze; James W Mier; Patricia Sorokin; Richard I Fisher; C Appel; Wei Du
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3194-202.
2001: Joseph M Unger; Lawrence E Flaherty; P Y Liu; Kathy S Albain; vernon sondak
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials.
Cancer 2001;91(6):1148-55.
2001: Robert P Whitehead; Joseph M Unger; Lawrence E Flaherty; J R Eckardt; Sarah A Taylor; MUKUND DIDOLKAR; Wolfram E Samlowski; vernon sondak
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Investigational new drugs 2001;19(3):239-43.
2001: S Prakash; Brenda J Foster; M Meyer; Antoinette J Wozniak; Lance K Heilbrun; Lawrence E Flaherty; Mark M Zalupski; L Radulovic; Manuel Valdivieso; Patricia M LoRusso
Chronic oral administration of CI-994: a phase 1 study.
Investigational new drugs 2001;19(1):1-11.
2000: C Trivedi; Bruce G Redman; Lawrence E Flaherty; Omer Kucuk; Wei Du; Lance K Heilbrun; Maha Hussain
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Cancer 2000;89(2):431-6.
2000: Philip A Philip; Lawrence E Flaherty
Biochemotherapy for melanoma.
Current oncology reports 2000;2(4):314-21.
2000: John M Kirkwood; Joseph G Ibrahim; vernon sondak; J Richards; Lawrence E Flaherty; Marc S Ernstoff; T J Smith; Uma Rao; M Steele; Ronald Blum
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2444-58.
2000: vernon sondak; Lawrence E Flaherty
Adjuvant high-dose interferon revisited.
Cancer journal (Sudbury, Mass.) 2000;6(3):132-4.
2000: Lawrence E Flaherty
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
The cancer journal from Scientific American 2000;6 Suppl 1():S15-20.
1999: Kim Margolin; PY Liu; Joseph M Unger; WS Fletcher; Lawrence E Flaherty; W J Urba; Evan M Hersh; L E Hutchins; Jeffrey A Sosman; John W Smith; Geoffrey R Weiss; vernon sondak
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
Journal of cancer research and clinical oncology 1999;125(5):292-6.
1999: vernon sondak; PY Liu; Lawrence E Flaherty; WS Fletcher; P Periman; David R Gandara; Sarah A Taylor; S P Balcerzak; F L Meyskens
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
The cancer journal from Scientific American 1999;5(1):41-7.
1998: Lawrence E Flaherty; Joseph M Unger; P Y Liu; WC Mertens; vernon sondak
Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.
American journal of clinical oncology 1998;21(6):568-72.
1998: Robert P Whitehead; Joseph M Unger; J Wendall Goodwin; M J Walker; J A Thompson; Lawrence E Flaherty; vernon sondak
Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(6):440-6.
1998: David C Smith; Bruce G Redman; Lawrence E Flaherty; L Li; Myla S Strawderman; Kenneth J Pienta
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
Urology 1998;52(2):257-60.
1998: Marc K Wallack; Muthukumaran Sivanandham; Charles M Balch; M M Urist; K I Bland; D Murray; William A Robinson; Lawrence E Flaherty; J M Richards; Alfred A Bartolucci; L Rosen
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Journal of the American College of Surgeons 1998;187(1):69-77; discussion 77-9.
1998: Bruce G Redman; David C Smith; Lawrence E Flaherty; Wei Du; Maha Hussain
Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1844-8.
1998: Bruce G Redman; Gilda G Hillman; Lawrence E Flaherty; Jeffrey D Forman; B Dezso; Gabriel P Haas
Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):283-6.
1998: Kim Margolin; PY Liu; Lawrence E Flaherty; Jeffrey A Sosman; M J Walker; John W Smith; WS Fletcher; Geoffrey R Weiss; Joseph M Unger; vernon sondak
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):664-9.
1997: Lawrence E Flaherty; P Y Liu; J Unger; vernon sondak
Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.
American journal of clinical oncology 1997;20(6):600-4.
1997: Marc K Wallack; Muthukumaran Sivanandham; K Ditaranto; P Shaw; Charles M Balch; M M Urist; K I Bland; D Murray; William A Robinson; Lawrence E Flaherty; J M Richards; L Rosen; Alfred A Bartolucci
Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.
Annals of surgery 1997;226(2):198-206.
1997: Philip A Philip; Lawrence E Flaherty
Treatment of malignant melanoma with interleukin-2.
Seminars in oncology 1997;24(1 Suppl 4):S32-8.
1997: Kenneth J Pienta; Peg Esper; Fred Zwas; R Krzeminski; Lawrence E Flaherty
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.
American journal of clinical oncology 1997;20(1):36-9.
1996: Kenneth J Pienta; Bruce G Redman; Peg Esper; Lawrence E Flaherty
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
American journal of clinical oncology 1996;19(5):500-3.
1996: K Katato; Lawrence E Flaherty; Mary Varterasian
Secondary acute myelogenous leukemia following treatment with oral etoposide.
American journal of hematology 1996;53(1):54-5.
1996: Lawrence E Flaherty; PY Liu; M S Mitchell; W S Fletcher; M J Walker; J Wendall Goodwin; R L Stephens; vernon sondak
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
American journal of clinical oncology 1996;19(2):108-13.
1996: Brenda J Foster; Patricia M LoRusso; E Poplin; Mark M Zalupski; Manuel Valdivieso; Antoinette J Wozniak; Lawrence E Flaherty; D A Kasunic; R H Earhart; Laurence H Baker
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
Investigational new drugs 1996;13(4):321-6.
1995: Patricia M LoRusso; Brenda J Foster; E Poplin; J McCormick; Michael J Kraut; Lawrence E Flaherty; Lance K Heilbrun; Manuel Valdivieso; Laurence H Baker
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1487-93.
1995: Frank L Meyskens; K J Kopecky; C W Taylor; R D Noyes; R J Tuthill; Evan M Hersh; Lynn Feun; James Doroshow; Lawrence E Flaherty; vernon sondak
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1995;87(22):1710-3.
1995: Bruce G Redman; T H Chou; Mark M Zalupski; Joseph Primo Uberti; Lawrence E Flaherty; M Dan; L Sensenbrenner
Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(2):115-8.
1995: M Slavik; PY Liu; E H Kraut; R B Natale; Lawrence E Flaherty; vernon sondak
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
Investigational new drugs 1995;13(2):143-7.
1995: Marc K Wallack; Muthukumaran Sivanandham; Charles M Balch; M M Urist; K I Bland; D Murray; William A Robinson; Lawrence E Flaherty; J M Richards; Alfred A Bartolucci
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.
Cancer 1995;75(1):34-42.
1995: Jeffrey A Sosman; Lawrence E Flaherty; PY Liu; W Fletcher; J A Thompson; A Hantel; V Sondak
A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
Investigational new drugs 1995;13(1):83-7.
1994: F A Momin; Mark M Zalupski; Lance K Heilbrun; Lawrence E Flaherty; G Fyfe; Laurence H Baker; Bruce G Redman
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):224-8.
1994: Bruce G Redman; Y Abubakr; T Chou; Peg Esper; Lawrence E Flaherty
Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):211-5.
1994: Kenneth J Pienta; Bruce G Redman; Maha Hussain; G Cummings; Peg Esper; C Appel; Lawrence E Flaherty
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2005-12.
1994: Maha Hussain; Kenneth J Pienta; Bruce G Redman; G D Cummings; Lawrence E Flaherty
Oral etoposide in the treatment of hormone-refractory prostate cancer.
Cancer 1994;74(1):100-3.
1993: Lawrence E Flaherty; William A Robinson; Bruce G Redman; R Gonzalez; S Martino; Michael J Kraut; Manuel Valdivieso; A R Rudolph
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
Cancer 1993;71(11):3520-5.
1992: Bruce G Redman; Lawrence E Flaherty; S Martino; Michael J Kraut; C Wisniewski; Manuel Valdivieso; J J Bander
Effect of calcium replacement on the hemodynamic changes associated with high dose interleukin-2 therapy.
American journal of clinical oncology 1992;15(4):340-3.
1992: E A Poplin; Thomas H Corbett; Lawrence E Flaherty; P Tarasoff; Bruce G Redman; Manuel Valdivieso; Laurence H Baker
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Investigational new drugs 1992;10(3):165-70.
1992: Bruce G Redman; Lawrence E Flaherty; T H Chou; Michael J Kraut; S Martino; Michael R Simon; Manuel Valdivieso; E Groves
Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(1):50-4.
1992: Lawrence E Flaherty; PY Liu; W S Fletcher; J Wendall Goodwin; Stanley P Balcerzak; D Daniels; R L Stephens; vernon sondak
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
Journal of the National Cancer Institute 1992;84(11):893-4.
1992: M Goel; Lawrence E Flaherty; S Lavine; Bruce G Redman
Reversible cardiomyopathy after high-dose interleukin-2 therapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(3):225-9.
1992: E Poplin; Harriet O Smith; B Behrens; Bruce G Redman; Lawrence E Flaherty; J Neidhart; D Alberts
SWOG 8825: melphalan GM-CSF: a phase I study.
Gynecologic oncology 1992;44(1):66-70.
1991: Lawrence E Flaherty; Antoinette J Wozniak; Bruce G Redman; Michael J Kraut; S Martino; Lance K Heilbrun; Manuel Valdivieso
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Cancer 1991;68(5):944-7.
1991: Bruce G Redman; Lawrence E Flaherty; T H Chou; Alexander Nakeff; K Pillote; Joseph Kaplan
Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(2):147-51.
1990: S Martino; B A Samal; Bruce G Redman; Lawrence E Flaherty; Michael J Kraut; Michael R Simon; Manuel Valdivieso
Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
Breast cancer research and treatment 1990;17(2):139-43.
1990: Lawrence E Flaherty; R Schwert; Bruce G Redman
Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
Journal of the National Cancer Institute 1990;82(16):1360.
1990: Bruce G Redman; Lawrence E Flaherty; T H Chou; Ayad Al-Katib; Michael J Kraut; S Martino; Ben D Chen; Joseph Kaplan; Manuel Valdivieso
A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1269-76.
1990: G R Birchfield; John H Ward; Bruce G Redman; Lawrence E Flaherty; Wolfram E Samlowski
Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.
The Western journal of medicine 1990;152(6):714-6.
1990: Lawrence E Flaherty; Bruce G Redman; Guy G. Chabot; S Martino; S M Gualdoni; Lance K Heilbrun; Manuel Valdivieso; E C Bradley
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Cancer 1990;65(11):2471-7.
1990: N W Baron; Lawrence Davis; Lawrence E Flaherty; J Muz; Manuel Valdivieso; G A Kling
Scintigraphic findings in patients with shoulder pain caused by interleukin-2.
AJR. American journal of roentgenology 1990;154(2):327-30.
1990: Guy G. Chabot; Lawrence E Flaherty; Manuel Valdivieso; Laurence H Baker
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
Cancer chemotherapy and pharmacology 1990;27(2):157-60.
1986: S J Shattil; H J Motulsky; P A Insel; Lawrence E Flaherty; L F Brass
Expression of fibrinogen receptors during activation and subsequent desensitization of human platelets by epinephrine.
Blood 1986;68(6):1224-31.
1986: James A Hoxie; Lawrence E Flaherty; B S Haggarty; J L Rackowski
Infection of T4 lymphocytes by HTLV-III does not require expression of the OKT4 epitope.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(2):361-3.